Aldeyra Therapeutics, INC

Aldeyra Therapeutics has entered into a lease agreement for approximately 4,067 square feet of office space in Concord, Massachusetts, to serve as its new corporate headquarters.

Aldeyra Therapeutics received FDA minutes regarding reproxalap NDA resubmission for dry eye disease and plans further FDA engagement.

Aldeyra Therapeutics director Martin J. Joyce has announced he will not stand for re-election at the 2026 annual meeting.

Aldeyra Therapeutics, Inc. announced the full repayment and termination of its $15 million Hercules Credit Facility.

Aldeyra Therapeutics received a Complete Response Letter from the FDA for its dry eye disease drug reproxalap, citing insufficient efficacy evidence.

Aldeyra Therapeutics' Chief Development Officer, Stephen G. Machatha, Ph.D., has voluntarily resigned to pursue other opportunities, with a transition plan in place until March 31, 2026.

Aldeyra Therapeutics announced its first quarter 2026 financial results, detailing a significant decrease in operating expenses and a net loss of $3.5 million.

Aldeyra Therapeutics reports a reduced net loss for Q3 2025, maintaining a stable cash position while its lead drug, reproxalap, awaits a critical FDA decision.

Aldeyra Therapeutics reports reduced net losses but faces continued regulatory hurdles for its lead dry eye drug, reproxalap, with a key partnership option unexercised.

Aldeyra Therapeutics reports a net loss for Q1 2025 and provides updates on its reproxalap NDA and other clinical programs.

Aldeyra Therapeutics' third quarter 2024 report reveals a net loss of $15.1 million, alongside updates on clinical programs and financial activities.

Aldeyra Therapeutics' second quarter 2024 report details a net loss of $24.9 million and a decrease in cash reserves, while highlighting ongoing clinical development and strategic agreements.

Aldeyra Therapeutics' 2025 annual report details reduced net losses, ongoing reproxalap regulatory delays, and strategic pipeline advancements.

Aldeyra Therapeutics files an amendment to its original Form 10-K to correct an administrative error in the consent of its independent registered public accounting firm.

Aldeyra Therapeutics navigates a critical period with its lead drug reproxalap awaiting FDA decision, while managing ongoing financial needs and strategic collaborations.

Aldeyra Therapeutics extends its lease agreement and files its annual report on Form 10-K, detailing financial results and business activities.

Aldeyra Therapeutics Director Nancy Miller-Rich acquired stock options for 73,318 shares of common stock.

Richard Douglas, a Director at Aldeyra Therapeutics, acquired stock options for 70,000 shares, with additional options for 19,909 and 2,323 shares, all exercisable at $1.72.

Aldeyra Therapeutics Director Gary M. Phillips acquired stock options for 70,000 shares of common stock.

Aldeyra Therapeutics Director William D. Clark acquired stock options for 72,323 shares of common stock.

Aldeyra Therapeutics Director Neal Walker acquired stock options for 73,318 shares, with exercise prices of $1.72, as detailed in a Form 4 filing.

Aldeyra Therapeutics Director Ben Bronstein acquired stock options for 70,000 shares of common stock.

Aldeyra Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect directors, ratify auditor appointments, and vote on executive compensation.

Aldeyra Therapeutics has scheduled its 2025 Annual Meeting for June 10, 2025, and is seeking stockholder votes on key proposals including the election of directors and ratification of the company's accounting firm.

Aldeyra Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on June 10, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory vote.

Aldeyra Therapeutics has scheduled its annual stockholder meeting for June 4, 2024, and is seeking votes on the election of directors, ratification of the company's accounting firm, and executive compensation.

Aldeyra Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 4, 2024, covering director elections, auditor ratification, and executive compensation.

The Vanguard Group reports 0% beneficial ownership in Aldeyra Therapeutics Inc. following an internal realignment.

Perceptive Advisors and its affiliates reported a beneficial ownership of 8.7% in Aldeyra Therapeutics, Inc., holding 5,222,311 common shares.

Perceptive Advisors and its affiliates have increased their beneficial ownership in Aldeyra Therapeutics, Inc. to 6.8% of common stock.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a beneficial ownership of 8.2% in Aldeyra Therapeutics, Inc., totaling 4,875,851 common shares.